Viking Therapeutics, Inc.VKTX
Market cap
$4B
P/E ratio
| 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | 3 | 2 | 1 | 3 | 4 | 6 | 6 | 9 | 17 | 30 |
| Cash from operations | -8,731,494 | -11,071,263 | -14,757,767 | -19 | -25 | -22 | -48 | -48 | -73 | -88 |
| Cash from investing | -13,470,042 | 3 | -1,729,707 | -266 | 7 | 42 | 38 | 55 | -179 | -553 |
| Repurchases of common stock | 38 | 229 | - | - | - | - | - | 7 | - | - |
| Cash from financing | 22 | 10 | 22 | 300 | 1 | 1 | 7 | 4 | 271 | 612 |